Rhythm Pharmaceuticals, Inc.
RYTM
株式のランク
#3014
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
株価
$88.37
最終同期: 2026-10-19
時価総額
$6.08B
変化（1日）
2.55%
変化（1年）
-21.37%
国
US
取引 Rhythm Pharmaceuticals, Inc. (RYTM)
カテゴリー
Healthcare
Rhythm Pharmaceuticals, Inc.（RYTM）の利益
Jun 2026 時点の利益 TTM: $-204.28M
Rhythm Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は $-204.28M です。2023 年には $-184.11M の利益を上げ、これは 2022 年の利益 $-181.12M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Rhythm Pharmaceuticals, Inc. の利益の推移（2012 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-204.28M | -21.51% |
| 2024 | $-260.26M | 41.36% |
| 2023 | $-184.11M | 1.65% |
| 2022 | $-181.12M | 160.18% |
| 2021 | $-69.61M | -48.05% |
| 2020 | $-134.00M | -4.78% |
| 2019 | $-140.73M | 90.01% |
| 2018 | $-74.06M | 119.72% |
| 2017 | $-33.71M | 30.29% |
| 2016 | $-25.87M | 133.65% |
| 2015 | $-11.07M | 70.54% |
| 2014 | $-6.49M | -69.70% |
| 2013 | $-21.43M | 18.21% |
| 2012 | $-18.13M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -2,682.23% |
US
|
|
| $-3.09B | 1,411.18% |
US
|
|
| $-4.02B | 1,866.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,054.90% |
NL
|
